CTOs on the Move

Aurinia Pharmaceuticals

www.auriniapharma.com

 
Aurinia is a global clinical stage biopharmaceutical company focused on developing and commercializing innovative products to treat identifiable patient populations that are suffering from serious diseases with a high unmet medical need. The company is headquartered in Victoria, BC and focuses its development efforts globally.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.auriniapharma.com
  • 500 W Office Center Drive Suite 400
    Fort Washington, PA USA 19034
  • Phone: 250.708.4272

Executives

Name Title Contact Details
Darin Wilson
Senior Director, Enterprise IT Profile

Funding

Aurinia Pharmaceuticals raised $28.75M on 12/29/2016
Aurinia Pharmaceuticals raised $173.1M on 03/20/2017
Aurinia Pharmaceuticals raised $191.7M on 12/12/2019

Similar Companies

Montesino Associates

Montesino Associates is a Sparta, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HiberCell

Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that.

Gene Logic

Gene Logic is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inovio

Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to safely produce a robust immune response to destroy and clear high-risk HPV 16 and 18, which are responsible for 70% of cervical cancer, 90% of anal cancer and 69% of vulvar cancer. In addition to HPV, Inovio`s optimized plasmid design and delivery technology have been demonstrated to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. Inovio`s most advanced clinical program, VGX-3100, is in Phase 3 development for the treatment of HPV-related cervical pre-cancer. Also in development are Phase 2 immuno-oncology programs targeting HPV-related cancers, GBM, and prostate cancer, as well as externally funded vaccine development programs in Zika, MERS, Lassa, HIV, and COVID-19. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency, GeneOne Life Science, HIV Vaccines Trial Network, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron, Roche/Genentech, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. Inovio also is a proud recipient of 2020 Women on Boards “W” designation recognizing companies with more than 20% women on their board of directors.

IntegenX

IntegenX is a Pleasanton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.